Encompass Health Opens First Connecticut Rehab Hospital in Danbury
EHC opens its first Connecticut rehab hospital in Danbury, boosting its nationwide expansion and meeting rising demand for specialized care.
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding
A Media Snippet accompanying this announcement is available by clicking on this link.
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DUBLIN, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to five ( 5 ) new ...
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ ( sodium oxybate ) for Extended-Release Oral Suspension at World Sleep 2025
- 17 abstracts accepted, including one oral presentation ...
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ ( sodium oxybate ) for Extended-Release Oral Suspension at World Sleep 2025 - Avadel Pharmaceuticals ( NASDAQ:AVDL )
- 17 abstracts accepted, including one oral presentation - - Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates -
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
- Expands Avadel's pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia ...
This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Archrock ( NYSE:AROC ) , Alkermes ( NASDAQ:ALKS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Compass Point analyst Ed Engel initiated coverage on Bullish BLSH with a Neutral rating and ...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: ...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc AVDL, a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
HUM Expands Musculoskeletal Care Access With New Value-Based Tie-Ups
Humana teams up with Vori Health, HOPCo and TailorCare to expand value-based musculoskeletal care for Medicare Advantage members.
Acadia & ECU Health Expand Behavioral Care Access in North Carolina
ACHC opens a 144-bed hospital with ECU Health in Greenville, NC, boosting care access and expanding its behavioral health reach.
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
CORT's stock is up 39.6% year to date as relacorilant nears FDA approval for Cushing's syndrome and expands into cancer studies.
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
Are Options Traders Betting on a Big Move in Avadel Pharmaceuticals Stock?
Investors need to pay close attention to Avadel Pharmaceuticals stock based on the movements in the options market lately.
Avadel ( AVDL ) Q2 Revenue Jumps 64%
Avadel Pharmaceuticals Plc ( NASDAQ:AVDL ) , a biopharmaceutical company focused on transforming medicines to improve lives, released its earnings for Q2 2025 on August 7, 2025. The headline news is significant: the company delivered GAAP revenue and earnings that exceeded Wall Street's ...
Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz - Avadel Pharmaceuticals ( NASDAQ:AVDL )
ASL estimates Avadel missed $600 million-$800 million in revenue by delaying Lumryz patient conversion. The company's market cap dropped from $2.5 billion to $900 million as CEO compensation reached $7.4 million. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this ...
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
DUBLIN, June 30, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit ( the "Appeals ...
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, June 30, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc AVDL, a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit ( the "Appeals Court" ) affirmed ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DUBLIN, June 16, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to two new ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, June 16, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc AVDL, a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to two new employees to purchase ...
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ ( sodium oxybate ) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
DUBLIN, June 05, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation ( ODD ) from the U.S.
Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, Ireland, May 29, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc AVDL, a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on ...
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer
DUBLIN, May 13, 2025 ( GLOBE NEWSWIRE ) -- DUBLIN, May 13, 2025 - Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer.
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, May 13, 2025 ( GLOBE NEWSWIRE ) -- DUBLIN, May 13, 2025 - Avadel Pharmaceuticals plc AVDL, a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer.
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
DUBLIN, April 10, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to nine ( 9 ) new ...
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference
DUBLIN, April 08, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference.
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, April 08, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc AVDL, a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference.
Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference
DUBLIN, April 01, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24th Annual Needham Healthcare ...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3
DUBLIN, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m.
Aging Population Fuels Nocturia Market Growth, Projected to Reach US$ 8.5 Billion by 2034 - Latest Research Report by TMR
Wilmington, Delaware, Transparency Market Research Inc. -, Feb. 04, 2025 ( GLOBE NEWSWIRE ) -- The global nocturia market ( Pasar Nocturia ) , valued at US$ 3.7 billion in 2023, is projected to grow at a CAGR of 8.0%, reaching US$ 8.5 billion by 2034.
Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement
DUBLIN, Ireland, Jan. 22, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and ...
Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ - Avadel Pharmaceuticals ( NASDAQ:AVDL ) , iShares Biotechnology ETF ( NASDAQ:IBB )
Sales of its narcolepsy drug, LUMRYZ rose by 150% YoY. AVDL expects net product revenue for 2025 in the range of $240 million to $260 million. Avadel Pharmaceuticals AVDL slipped by 25.63% in after-hours on Wednesday after it missed the fourth quarter sales estimate by 5.12%.
Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch - Avadel Pharmaceuticals ( NASDAQ:AVDL )
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of December 31, 2024, including 600 patients that initiated therapy in the ...
Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of December 31, 2024, including 600 patients that initiated therapy in the ...
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
DUBLIN, Jan. 03, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m.
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
DUBLIN, Nov. 13, 2024 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference ...
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, Nov. 13, 2024 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc AVDL, a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on ...
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation
DUBLIN, Oct. 31, 2024 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced that yesterday, the U.S. District Court for the District of Columbia ( "Court" ) ruled in favor of the Food and ...
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Carvana ( NYSE:CVNA )
Shares of Carvana Co. CVNA rose in today's pre-market trading after the company reported better-than-expected third-quarter financial results. Carvana reported third-quarter revenue of $3.66 billion, beating the consensus estimate of $3.45 billion, according to Benzinga Pro.
Avadel Obtains FDA Nod for Label Expansion Of Narcolepsy Drug Lumryz - Alnylam Pharmaceuticals ( NASDAQ:ALNY ) , ANI Pharmaceuticals ( NASDAQ:ANIP )
Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) announced that the FDA has approved its supplemental new drug application ( sNDA ) seeking label expansion of Lumryz. The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness EDS in patients ...
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz
The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5!
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ ( sodium oxybate ) Extended-Release Oral Suspension ( CIII ) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness ( EDS ) in patients 7 years of age and older with ...
Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing ( sodium oxybate ) Extended-Release Oral Suspension ( CIII ) - Avadel Pharmaceuticals ( NASDAQ:AVDL )
- Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens - - 91% reported being better able to sleep through the night after switching to LUMRYZ -
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, Ireland, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: ...
Stocks Showing Rising Market Leadership: Avadel Pharmaceuticals Earns 81 RS Rating
Avadel Pharmaceuticals ( AVDL ) had its Relative Strength ( RS ) Rating upgraded from 77 to 81 Friday.
Looking At Avadel Pharmaceuticals's Recent Unusual Options Activity - Avadel Pharmaceuticals ( NASDAQ:AVDL )
Deep-pocketed investors have adopted a bearish approach towards Avadel Pharmaceuticals AVDL, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as ... - PR Newswire
QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as ... PR ...
Stocks To Watch: Avadel Pharmaceuticals Sees Relative Strength Rating Rise To 85
On Wednesday, Avadel Pharmaceuticals ( AVDL ) reached an important technical milestone, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 85, up from 79 the day before.